These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32329886)

  • 1. Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy.
    Moryl N; Filkins A; Griffo Y; Malhotra V; Jain RH; Frierson E; Inturrisi C
    J Opioid Manag; 2020; 16(2):111-118. PubMed ID: 32329886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
    Coish R; Hardial J
    J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine-Naloxone in the Setting of Kratom Withdrawal, Opioid Use Disorder, and Stage IV Lung Adenocarcinoma.
    Hong S; Zimmerman PE; Rao V; Markwalter DW
    J Palliat Med; 2023 May; 26(5):734-736. PubMed ID: 36580544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States.
    Parish WJ; Mark TL; Zarkin GA; Weber E
    Addiction; 2022 Jan; 117(1):141-150. PubMed ID: 34033177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
    Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
    Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing acute and postsurgical pain management in patients receiving buprenorphine or buprenorphine/naloxone.
    Jones AC; Tillman F; Kahlon C; Seys R; Pepin M
    J Am Pharm Assoc (2003); 2024; 64(3):102035. PubMed ID: 38364887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose tramadol conversion to buprenorphine-naloxone.
    Kirk JK; Boyd CT; Cassidy-Vu L; McRae LP; Strickland HE; Fagan EB
    J Opioid Manag; 2023; 19(2):187-190. PubMed ID: 37270427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial.
    Ellerbroek H; van den Heuvel SAS; Dahan A; Timmerman H; Kramers C; Schellekens AFA
    Addict Sci Clin Pract; 2022 Sep; 17(1):47. PubMed ID: 36057608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.
    Fitzgerald Jones K; Khodyakov D; Arnold R; Bulls H; Dao E; Kapo J; Meier D; Paice J; Liebschutz J; Ritchie C; Merlin J
    JAMA Oncol; 2022 Aug; 8(8):1107-1114. PubMed ID: 35771550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series.
    Murray JP; Pucci G; Weyer G; Ari M; Dickson S; Kerins A
    Addict Sci Clin Pract; 2023 Jun; 18(1):38. PubMed ID: 37264449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Kratom Withdrawal and Dependence With Buprenorphine/Naloxone: A Case Series and Systematic Literature Review.
    Weiss ST; Douglas HE
    J Addict Med; 2021 Apr; 15(2):167-172. PubMed ID: 32858563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating opioid use disorder with rapid micro induction technique of sublingual buprenorphine/naloxone in an outpatient setting-a case report.
    Martell JP; Konakanchi JS; Sethi R
    J Addict Dis; 2022; 40(3):439-443. PubMed ID: 35072589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expert Panel Consensus on Management of Advanced Cancer-Related Pain in Individuals With Opioid Use Disorder.
    Merlin JS; Khodyakov D; Arnold R; Bulls HW; Dao E; Kapo J; King C; Meier D; Paice J; Ritchie C; Liebschutz JM
    JAMA Netw Open; 2021 Dec; 4(12):e2139968. PubMed ID: 34962565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing A Rapid Transfer from Opioid Full Agonist to Buprenorphine: "Ultrarapid Micro-Dosing" Proof of Concept.
    Azar P; Mathew N; Mahal D; Wong JSH; Westenberg JN; Schütz CG; Greenwald MK
    J Psychoactive Drugs; 2023; 55(1):94-101. PubMed ID: 35152847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: A finite mixture model.
    Vest NA; McPherson S; Burns GL; Tragesser S
    Drug Alcohol Depend; 2020 Apr; 209():107940. PubMed ID: 32135429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low Dose Buprenorphine Induction With Full Agonist Overlap in Hospitalized Patients With Opioid Use Disorder: A Retrospective Cohort Study.
    Bhatraju EP; Klein JW; Hall AN; Chen DR; Iles-Shih M; Tsui JI; Merrill JO
    J Addict Med; 2022 Jul-Aug 01; 16(4):461-465. PubMed ID: 34954743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.